Compare Vanguard International High Dividend Yield ETF (VYMI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard International High Dividend Yield ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard International High Dividend Yield ETF trades at $101.33, while State Street SPDR S&P Biotech ETF trades at $154.32. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| VYMI | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $101.60 | $164.28 |
52-Week Low | $79.95 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYMI trades at $100.23, down 0.65% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF offers international high dividend yield exposure with over 1,500 stocks and has delivered 10.8% annualized returns over 10 years. Recent institutional buying by D.A. Davidson & CO. increased their position by 265.6% during the latest quarter.
VYMI presents a compelling international diversification opportunity with strong dividend growth potential, though currency fluctuations and global economic conditions pose risks. The ETF's low 0.07% expense ratio and broad diversification across developed and emerging markets provide defensive characteristics in uncertain market environments.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
